QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

$2.24
+0.20 (+9.56%)
(As of 03:59 PM ET)
Today's Range
$2.02
$2.26
50-Day Range
$1.71
$3.07
52-Week Range
$1.32
$3.97
Volume
789,062 shs
Average Volume
992,756 shs
Market Capitalization
$567.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Lyell Immunopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
146.1% Upside
$5.50 Price Target
Short Interest
Bearish
8.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Lyell Immunopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.91) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

490th out of 938 stocks

Pharmaceutical Preparations Industry

228th out of 432 stocks

LYEL stock logo

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Stock Price History

LYEL Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Lyell Immunopharma Inc (LYEL)
Heather D. Lyell
Why Lyell Immunopharma Shares Are Rising Today
Lyell Immunopharma reports Q3 results
Lyell Immunopharma Shares Up 8% on Cellares Collaboration
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+158.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-234,630,000.00
Net Margins
-180,486.14%
Pretax Margin
-180,486.17%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$2.60 per share

Miscellaneous

Free Float
193,113,000
Market Cap
$539.96 million
Optionable
Optionable
Beta
-0.50
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 72)
    Founder & Executive Chairman
    Comp: $80k
  • Dr. Lynn Seely M.D. (Age 65)
    Ph.D., President, CEO & Director
    Comp: $430.69k
  • Mr. Charles W. Newton (Age 52)
    Chief Financial Officer
    Comp: $1.72M
  • Mr. Stephen J. Hill (Age 54)
    Chief Operating Officer
    Comp: $1.04M
  • Dr. Gary Lee Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $639.91k
  • Ms. Elizabeth Homans (Age 58)
    Consultant
    Comp: $1.99M
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D. (Age 63)
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Senior Vice President of Communications & Investor Relations

LYEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LYEL shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price target for 2024?

2 analysts have issued 12-month price targets for Lyell Immunopharma's shares. Their LYEL share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 146.1% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2024?

Lyell Immunopharma's stock was trading at $1.94 on January 1st, 2024. Since then, LYEL stock has increased by 15.2% and is now trading at $2.2350.
View the best growth stocks for 2024 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its earnings results on Wednesday, February, 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative trailing twelve-month return on equity of 32.67%.

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an IPO on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.40%), Vanguard Group Inc. (5.35%), WuXi AppTec Co. Ltd. (3.25%), Price T Rowe Associates Inc. MD (2.64%), Price T Rowe Associates Inc. MD (2.64%) and Northern Trust Corp (0.59%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners